CD24 and breast cancer: Specifically, in luminal breast cancers, which constitute 70% of all breast cancers, it is critical to assess the tumorigenicity and BCSC-like properties of CD44low/CD24–/low/ALDH– cells, because this subpopulation reflects the major luminal breast cancer phenotype.